 The company traded on the NASDAQ exchange under the ticker symbol BIVV until Sanofi completed its acquisition on March 8, 2018.In May 2016 Biogen announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company.In August, Biogen announced they would call the spun off company "Bioverativ" to show heritage with Biogen, and would be spun off in early 2017.